AETHLON MEDICAL INC (AEMD)

NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04

$1.82-5.70%

Close 2026-09-04 · 1-day change

QuarterlyIQ Insights · AEMD

News & Events

Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.

Type

Direction

28 matches

2026-08-13Item 2.02
AEMD — earnings beat
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings beatpositive
2026-07-31Item 3.03
AEMD — capital allocation — Material Modification to Rights of Security
Material Modification to Rights of Security Holders. On Jul y 30, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”). The…
Capital allocationneutral
2026-07-08Item 1.01
AEMD — M&A activity — Entry into a Material
Entry into a Material Definitive Agreement On July 6, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) (i) 263,000 shares (“Shares”) of common stock, par value $0.001 per share (the “Common Stock”), (ii) warrants to purchase 5,633,009 shares of Commo…
M&A activitypositive
2026-06-10Item 2.02
AEMD — earnings beat
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings beatpositive
2026-06-04Item 8.01
AEMD — debt issuance
Other Events. On December 23, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) relating to the offer and sale of shares of the Company's common stock, par value $0.001 per share (“Common Stock”), from time to time pursuant to that certain At Market Offering Agreement, dated March 24, 2022, as amended on December 19, 2025 (the “ATM Agreement”), by and bet…
Capital allocationdebt issuanceneutral
2026-02-23Item 5.02
AEMD — officer change
The excerpt is incomplete and does not provide enough information to determine the nature of the event.
Executive changeotherneutral
2026-02-12Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative
2026-01-26Item 1.01
AEMD — M&A activity — Entry into a Material Definitive
Entry into a Material Definitive Agreement. Amendment to Securities Purchase Agreement On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the C…
M&A activitypositive
2025-12-08Item 3.03
AEMD — capital allocation — Material
Material Modifications to Rights of Security Holders. The disclosure set forth under
Capital allocationneutral
2025-12-08Item 1.01
AEMD — private placement
Entry into a Material Definitive Agreement. PIPE Offering On December 5, 2025, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Company agreed to issue to the Purchaser, in a private placement (the “PIPE Offering”), (i) 596,452 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) (or pre-funded warrants in li…
Capital allocationprivate placementneutral
2025-11-12Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative
2025-10-22Item 3.01
AEMD — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 16, 2025, Aethlon Medical, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the…
Legal / regulatorynegative
2025-10-16Item 3.03
AEMD — capital allocation — Material Modification to Rights of Security
Material Modification to Rights of Security Holders. On October 14, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”). T…
Capital allocationneutral
2025-09-09Item 1.01
AEMD — M&A activity — Entry into a Material Definitive
Entry into a Material Definitive Agreement On September 4, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) (i) 4,047,780 shares (“Shares”) of common stock, par value $0.001 per share (the “Common Stock”), (ii) 5,000,000 warrants to purchase up to 5,…
M&A activitypositive
2025-08-13Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative
2025-06-27Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative
2025-03-17Item 3.02
AEMD — capital allocation — Unregistered Sales of Equity
Unregistered Sales of Equity Securities. The information set forth in
Capital allocationnegative
2025-03-17Item 1.01
AEMD — acquisition announced
Entry into a Material Definitive Agreement. Warrant Inducement Agreement On March 16, 2025, Aethlon Medical, Inc. (the “Company”) entered into a inducement offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and institutional holder (the “Holder”) of the Company’s outstanding Class A and Class B Warrants issued on May 17, 2024 (the “Existing Warrants”). Pursuant to the Agreement, the Holder, upon exercise, will receive a new unregistered Common…
M&A activityacquisition announcedpositive
2025-03-17Item 3.03
AEMD — capital allocation — Material
Material Modifications to Rights of Security Holders. The disclosure set forth under
Capital allocationneutral
2025-02-12Item 2.02
AEMD — earnings beat
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings beatpositive
2025-01-08Item 3.01
AEMD — legal / regulatory event — Notice of Delisting or Failure
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on June 27, 2024, Aethlon Medical Inc., a Nevada Corporation (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that for 31 consecutive trading days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on The Nas…
Legal / regulatorynegative
2024-11-13Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative
2024-10-03Item 5.02
AEMD — CEO transition
Chief Executive Officer — James B. Frakes: James B. Frakes was promoted to permanent Chief Executive Officer.
Executive changeinternal promotionneutral
2024-10-02Item 5.02
AEMD — officer change
The excerpt is incomplete and does not provide enough information to determine the nature of the event.
Executive changeotherneutral
2024-08-14Item 2.02
AEMD — earnings miss
Results of Operations and Financial Condition. The information provided below in “
Earnings preannouncementearnings missnegative

Coming next

General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.